

Appl. No. 09/998,667  
Amdt. dated August 1, 2003  
Response to Restriction Requirement

PATENT

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A method for identifying a compound that modulates T lymphocyte activation, the method comprising the steps of:
  - (i) contacting the compound with a TRAC1 polypeptide or a fragment thereof, the polypeptide or fragment thereof encoded by a nucleic acid that hybridizes under stringent conditions to an antisense nucleic acid corresponding to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1; and
  - (ii) determining the functional effect of the compound upon the TRAC1 polypeptide.
2. (Original) The method of claim 1, wherein the functional effect is measured *in vitro*.
3. (Original) The method of claim 2, wherein the functional effect is a physical effect.
4. (Original) The method of claim 2, wherein the functional effect is a chemical effect.
5. (Original) The method of claim 4, wherein the functional effect is determined by measuring ligase activity.
6. (Original) The method of claim 1, wherein the polypeptide is expressed in a host cell.
7. (Original) The method of claim 6, wherein the functional effect is a physical effect.

Appl. No. 09/998,667  
Amdt. dated August 1, 2003  
Response to Restriction Requirement

PATENT

8. (Original) The method of claim 6, wherein the functional effect is a chemical or phenotypic effect.
9. (Original) The method of claim 6, wherein the host cell is primary T lymphocyte.
10. (Original) The method of claim 6, wherein the host cell is a cultured T cell.
11. (Original) The method of claim 10, wherein the host cell is a Jurkat cell.
12. (Original) The method of claim 6, wherein the chemical or phenotypic effect is determined by measuring CD69 expression, intracellular Ca<sup>2+</sup> mobilization, Ca<sup>2+</sup> influx, ligase activity, or lymphocyte proliferation.
13. (Original) The method of claim 1, wherein modulation is inhibition of T lymphocyte activation.
14. (Original) The method of claim 1, wherein the polypeptide is recombinant.
15. (Original) The method of claim 1, wherein the TRAC1 polypeptide comprises an amino acid sequence of SEQ ID NO:1.
16. (Original) The method of claim 1, wherein the TRAC1 polypeptide is encoded by a nucleic acid comprising a nucleotide sequence of SEQ ID NO:2.
17. (Withdrawn) The method of claim 1, wherein the compound is an antibody.
18. (Withdrawn) The method of claim 1, wherein the compound is an antisense molecule.
19. (Original) The method of claim 1, wherein the compound is a small organic molecule.
20. (Withdrawn) The method of claim 1, wherein the compound is a peptide

Appl. No. 09/998,667  
Amdt. dated August 1, 2003  
Response to Restriction Requirement

PATENT

21. (Withdrawn) The method of claim 20, wherein the peptide is circular.

22. (Withdrawn) A method for identifying a compound that modulates T lymphocyte activation, the method comprising the steps of:

(i) contacting a T cell comprising a TRAC1 polypeptide or fragment thereof with the compound, the TRAC1 polypeptide or fragment thereof encoded by a nucleic acid that hybridizes under stringent conditions to an antisense nucleic acid corresponding to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1; and

(ii) determining the chemical or phenotypic effect of the compound upon the cell comprising the TRAC1 polypeptide or fragment thereof, thereby identifying a compound that modulates T lymphocyte activation.

23. (Withdrawn) A method for identifying a compound that modulates T lymphocyte activation, the method comprising the steps of:

(i) contacting the compound with a TRAC1 polypeptide or a fragment thereof, the TRAC1 polypeptide or fragment thereof encoded by a nucleic acid that hybridizes under stringent conditions to an antisense nucleic acid corresponding to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1;

(ii) determining the physical effect of the compound upon the TRAC1 polypeptide; and

(iii) determining the chemical or phenotypic effect of the compound upon a cell comprising the TRAC1 polypeptide or fragment thereof, thereby identifying a compound that modulates T lymphocyte activation.

24-46 (Withdrawn)